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Poptosis, the process by which cells commit suicide, is 
ubiquitous in both normal and diseased tissues,  and its 
mechanism is conserved in animal species from humans at 
least to nematodes. Apoptotic cells undergo a stereotypical 
set of changes--shrinkage, cleavage of nuclear DNA, con- 
densation of chromatin, fragmentation of the cytoplasm-- 
that distinguish them from cells dying by other means.  In 
embryogenesis, this process is required to form adult struc- 
tures (as when digits become separated) and to delete immune 
cell clones specific for self-antigens, and in adult tissues  it 
removes  cells  that  have  suffered damage  to  their genetic 
material.  Thus,  apoptosis helps to  establish  normal tissues 
and prevents cell proliferation that could otherwise lead to 
pathologic conditions such as autoimmunity or cancer. 
The recognition that a protein required for apoptosis in 
the worm, CED-3, is a homologue of the mammalian cys- 
teine proteinase interleukin 1[3-converting enzyme (ICE; 1) 
set the stage for much of the current work on apoptosis. It 
is now clear that at least five proteinases in the ICE family 
are expressed in mammalian cells,  and that the activity of 
some or all of  these enzymes is required for apoptosis to oc- 
cur (2). Inappropriate expression of intracellular proteinases 
including ICE has been shown to drive cells into the apop- 
totic program.  Conversely, normal  apoptosis  can be pre- 
vented by supplying cells with proteinase inhibitors such as 
CrmA, a viral protein that acts specifically on proteinases of 
the ICE family (3).  On the basis of results such as these, it 
seems clear that proteolysis is crucially involved in apopto- 
sis, but it is much less clear why this is so.  Apoptotic cells 
do not simply proteolyze themselves out of existence, and 
at least in the early stages of the process when the cell be- 
comes irreversibly committed to dying, the proteinases in- 
duced  are  extremely limited  in  their  specificity and  the 
number of target proteins is small. Evidently, proteolysis of 
certain key molecules serves to flip a switch, initiating a se- 
ries of steps  that culminate in the death of the cell and its 
processing into apoptotic fragments that can be phagocy- 
tosed by neighboring cells. 
Valuable hints about the nature of this switch come from 
the work of Casciola-Rosen et al.  (4)  in this issue  of the 
Journal of Experimental Medicine. In previous work (2, 5-10) 
these and other investigators identified several proteins that 
are targets ofapoptotic proteolysis, and therefore are candi- 
dates to be part of the switch. In the current study, they use 
a specific inhibitor ofapopain, a proteinase of the ICE faro- 
ily, and show by several criteria that apopain rather than 
ICE is responsible for the proteolysis they observe in apop- 
totic cells.  This is consistent with the  observation that in 
mice deficient for ICE, apoptosis still occurs in most cell types. 
Many of the known proteolytic targets are localized in the 
nucleus of normal cells: lamins; globular actin; the nuclear 
mitotic apparatus protein NuMA; the U1-70 kD protein, a 
component of the KNA splicing machinery; the  enzyme 
poly(ADP-ribose) polymerase (PARP); and the catalytic sub- 
unit  of the DNA-dependent protein kinase  (DNA-PK~s). 
Of these, U1-70 kD, PARP and DNA-PKc~ are believed to 
be cleaved by apopain (5, 8, 10), and at least the latter two 
appear to  be  involved in  regulating  the  cell cycle in  re- 
sponse to DNA damage. This function suggests a model for 
the  apoptotic switch in which  damage  to DNA  activates 
apopain to cleave a set of nuclear proteins that control the 
progression of cells through the cell cycle or commit it to 
apoptosis. 
DNA  Damage and the G1  Checkpoint 
Progression of  post-mitotic (G1) cells into the DNA syn- 
thesis  (S) phase of the cell cycle is driven by heterodimeric 
protein kinases  consisting of cyclins and cyclin-dependent 
kinases (cdk). In late G1, for example, cyclin E  pairs with 
cdk2  to form an  active kinase  that is  required to  initiate 
DNA replication (reviewed in reference 11). When normal 
cells are exposed to ionizing radiation or other treatments 
that lead to DNA strand breakage, this progression does not 
take place. Rather, the inhibitory subunit p21 forms a com- 
plex with G1  cyclin-cdk heterodimers, causing the cell to 
remain in G1 (12). Because this blockade of the cell cycle is 
typically transient  and  is  induced  by  damage  to  the  ge- 
nome, it is described as the G1 DNA damage checkpoint, 
one of  several known control points in the cell cycle. A key 
regulator of the G1  checkpoint, as well as of DNA repair 
and apoptosis, is the tumor suppressor protein p53 (Fig.  1). 
p53 is a transcription factor that is induced in cells with 
DNA  damaged by ionizing radiation  or other treatments 
(13,  14). p53 initiates the synthesis of  p21 and other nuclear 
proteins,  including  the  growth  arrest and DNA  damage- 
induced protein Gadd45, which binds to the proliferating 
cell nuclear antigen (PCNA). Gadd45 appears to potentiate 
DNA repair in nuclear extracts (reference 15 but also  see 
reference 16 for some contradictory data),  p21 and Gadd45 
have distinct roles in the G1 checkpoint. As noted, p21 binds 
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Figure  1.  Proposed fimctions 
of target substrates (boht) of ICE 
family proteinases in  regulating 
the G1 checkpoint and apoptosis 
in  response to  DNA  damage. 
p53 is central to G1  arrest. The 
upper  panels oudine  the  steps 
leading to  cell cycle arrest and 
DNA repair after damage, p53 
may be induced by at least three 
distinct pathways. The activities 
of the  nuclear enzymes PARP 
and  DNA-PK  are  induced di- 
rectly  by  DNA  strand breaks, 
and contribute to p53 activation. 
ATM, a major regulator of p53, 
may induce p53  by an  indirect 
mechanism, p53-dependent cy- 
cle  checkpoint  control  is  then 
mediated through induction of 
transcription of p21, which in- 
hibits the cyclin-cdk complex, and Gadd 45, which binds to PCNA. p53 activation is also central to induction ofapoptosis (botwm). In this case, p53 in- 
duction by DNA damage leads to activation of  the ICE family proteinases and, hence, the degradation of  the target proteins globular actin, DNA-PK and 
PARP, whereas degradation of  nuclear actin may free DNase I to initiate DNA cleavage. Proteolysis of  PARP and DNA-PKcs (and of  a number of  other 
potential substrates including ATM, Ref-1 and FRAP) may compromise the DNA repair and cell cycle delay functions shown in the upper panel and 
could lead to efficient execution of the death program. 
to  and  directly inhibits  the  S-phase-promoting activity of 
the cyclin-cdk complex.  In addition, p21  forms a complex 
with  PCNA  that  inhibits  DNA  polymerase  activity,  thus 
directly  opposing  the  process  of DNA  replication  (13). 
Cells  lacking p53  can,  by means  of uncharacterized  path- 
ways, still induce Gadd45 in response to DNA damage, but 
they proceed into S phase without activating a  G1  check- 
point. 
Mechanisms of  p53 Activation 
The induction of p53 by DNA strand breaks is complex 
and not fully understood. Several mechanisms are involved, 
but it is not yet clear whether they represent steps on a sin- 
gle pathway or multiple  independent pathways, all leading 
to increased p53 expression or activation. One major regu- 
lator  of p53  function  is  the  ATM  protein,  which  is  defi- 
cient in  patients  suffering from the  recessive  neurological 
disorder  ataxia-telangiectasia  (A-T;  reviewed  in  reference 
17). ATM appears from its sequence to be a kinase,  and its 
activity is required for the G1  checkpoint, but it is not yet 
clear what its  substrates  are or if they interact with known 
inducers of S phase. A-T patients' lymphocytes lack the nor- 
real G1 checkpoint control. After irradiation,  these ceils pro- 
ceed into  S phase  without  repairing  chromosomal breaks, 
and  subsequently  die  by  apoptosis  (17).  This  heightened 
apoptotic response is attributed  to misregulation of p53,  as 
described below, and is likely to underlie  the nervous sys- 
tem degeneration seen in these patients. 
Like ATM, PARP and DNA-PK are beheved to contrib- 
ute to p53 induction.  PARP is a modular protein compris- 
ing an NH2-terminal DNA binding domain, an auto-mod- 
ification domain  and a  COOH-terminal  catalytic domain. 
PARP binds  specifically to sites  of DNA damage and be- 
comes  activated  to  transfer  ADP-ribose  onto  various  nu- 
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clear proteins, including PAR,  P  itself (18).  The role of this 
protein  modification  is  uncertain  despite  considerable  in- 
terest and speculation,  and the mystery was only deepened 
when  PARP-deficient  mice  were  found  to  be  normal  in 
DNA repair and radiosensitivi W (19). However, in cell cul- 
ture  experiments  with  cells  either genetically deficient for 
PARP or depleted of NAD, the substrate of the enzyme, it 
appears that PARP activi W is required for p53 synthesis in- 
duced by DNA strand breaks (20). Why these results are not 
reflected in the phenotype of the mutant animal is a ques- 
tion that will certainly stimulate more research, but it seems 
likely that cells possess several paths to p53 induction. 
DNA-PK is  another  enzyme activated  by DNA  breaks 
(21). The DNA-PK holoenzTme consists ofa 350-kD cata- 
lytic subunit associated with the proteins Ku70 and Ku80. 
The Ku proteins  bind specifically to DNA lesions  and re- 
cruit the DNA-PKc, to the site of damage, leading to its ac- 
tivation.  Again,  although  numerous  substrates  of this  en- 
zyme have been identified, their role in downstream events 
is uncertain.  One of these substrates is p53, and it has been 
suggested that phosphorylation of p53  causes this normally 
short-lived protein  to be stabilized.  Whatever the  mecha- 
nism,  DNA-PK  seems  to  be  important  in  the  repair  of 
DNA breaks.  A  defect in the DNA-PKc~ is responsible for 
severe combined immunodeficiency (SCID) in mice. SCID 
animals are radiosensitive and lack functional immune cells 
owing to a defect in DNA recombination (22, 23). Because 
maturation of B and T  lymphocytes requires DNA breakage 
and  rejoining in the  immunoglobuhn  and  T  cell  receptor 
loci before the cells  can replicate their DNA, it may be that 
this process normally activates a G1 checkpoint, just as arti- 
ficially induced DNA damage does. Absent DNA-PK activ- 
ity,  SCID cells  fail  to rejoin broken DNA  ends,  although 
they have been found to induce G1  arrest after irradiation, suggesting that p53  can be induced by mechanisms inde- 
pendent of DNA-PK. 
The Decision  to Stop or Die 
DNA strand breaks cause cells to arrest before initiating 
S phase, but it does not follow that they will remain in G1 
indefinitely as repairs proceed.  Indeed, depending on ex- 
perimental conditions, cells may not accumulate in G1 at all, 
but rather apoptose rapidly and quantitatively. Surprisingly, 
p53, the modulator that is central to G1  arrest after DNA 
breaks, is also required to induce apoptosis under the same 
conditions. In normal cells, drug- or radiation-induced DNA 
damage causes ICE family proteinases to be activated, com- 
mitting cells to apoptosis.  In cells lacking p53, both the apop- 
totic  response  and  the  G1  checkpoint response to  DNA 
damage are compromised. 
If p53  induction initiates both the  G1  checkpoint and 
the apoptotic program, how does a cell determine which 
path to take? The answer emerging to this critical question 
is that it opts to do both.  Guillouf et al.  (24)  recently re- 
ported that by transfecting p53-deficient cells with a tem- 
perature-sensitive p53, they can provoke apoptosis by shifting 
the culture to the permissive temperature, without radiation 
or drugs to damage DNA. If, however, they simultaneously 
transfect cells with cDNA encoding Bcl-2, an inhibitor of 
ICE  activation, cells  arrest in  G1  and only slowly initiate 
apoptosis.  In  both  transfected  populations,  downstream 
genes regulated by p53 are expressed in a similar manner, 
including the G1 arrest genes p21 and Gadd45 and the apop- 
totic regulators Bax and the endogenous Bcl-2  (24).  These 
results indicate that p53 activation initiates both pathways, 
and that which one predominates may reflect the level of 
anti-apoptotic protection the cell enjoys, in this case from 
the  overexpression of Bcl-2.  Others have shown that the 
presence of cytokines such as insulin-hke growth factor-2 
can maintain cells in G1 arrest by promoting expression of 
p21. If this survival factor is depleted at the time of irradia- 
tion, cells apoptose rather than remaining in G1  (25).  To- 
gether, these data show that at least the early events initiat- 
ing the two pathways are shared and that subtle factors such 
as cell type and culture conditions and perhaps the nature 
and extent of DNA damage can force the outcome in ei- 
ther direction. The ATM protein, which has been shown 
to induce checkpoints at G1 and elsewhere in the cell cy- 
cle, appears to inhibit p53-dependent apoptosis (17, 26) but 
a direct effect of  ATM on ICE family proteinases has not been 
established. 
Proteolysis  in Apoptosis 
Of the known proteolytic substrates cleaved in apoptosis, 
several would appear to be structural rather than regulatory 
molecules. The nuclear lamins provide a scaffold underly- 
ing the nuclear envelope, and it may be necessary to de- 
grade  these proteins  to  release bound  transcription  com- 
plexes and break the cell down into apoptotic fragments. In 
addition,  the nucleus is a highly organized structure. Dis- 
rupting this structure by degrading the lamins  may make 
the nuclear DNA more accessible  to cleavage by nucleases, 
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thus promoting internucleosomal DNA cleavage and chro- 
matin condensation, two hallmarks of apoptotic death. The 
nuclear protein NuMA is phosphorylated and cleaved very 
early in response to DNA damage in thymocytes, and it has 
been suggested that these events set the stage for later events 
such as lamin proteolysis (7, 9). Actin has been found to be 
cleaved by ICE and possibly other related proteinases (6), 
and the degradation of such an important cytoskeletal pro- 
tein would obviously compromise cellular structure and could 
facilitate cell fragmentation. However, it is not clear that fila- 
mentous actin is degraded by ICE. Kayalar and colleagues 
(6) have proposed a more subtle role for actin proteolysis in 
apoptosis:  activation of DNase  I  to  cleave nuclear DNA. 
They find that treating nuclear extracts with ICE flees la- 
tent DNase I from a catalytically inactive complex with glob- 
ular actin. This observation could provide a satisfying ex- 
planation for several otherwise puzzling observations,  namely, 
the presence of actin in the nucleus, the high affinity bind- 
ing of actin and DNase  I, and the role of actin as a pro- 
teolytic target in apoptosis. 
Cleavage of  PARP and DNA-PKcs may, as Casciola-Rosen 
et al. suggest (4), serve to cripple the DNA repair mecha- 
nisms  that  operate  during  G1  arrest.  As  described above 
(also see Fig.  1), these proteins act upstream of p53 to in- 
duce the G1 checkpoint and promote DNA repair. There- 
fore, cleaving these molecules could repress p53 and inhibit 
repair of the  DNA  damage  accompanying apoptotic  cell 
death. Because p53 is required to induce apoptosis in cells 
with DNA strand breaks, this model predicts that the acti- 
vation of p53 in apoptotic cells is transient, being limited 
by the destruction of  PARP and DNA-PKc~. p53 activation 
at the G1  checkpoint, on the other hand, is not subject to 
such  a negative feedback loop and may be maintained as 
long as DNA damage persists.  It is interesting to note that, 
like PARP and DNA-PKc~  , ATM  (27)  has  predicted sites 
for  cleavage by apopain,  including  one pentapeptide  se- 
quence in its putative catalytic domain that closely matches 
the PARP cleavage site. IfATM, too, should prove to be a 
target of apopain in apoptotic cells, this would support the 
idea that p53-dependent repair mechanisms need to be in- 
activated for apoptosis to proceed efficiently (Fig.  1). Sev- 
eral other proteins involved in DNA repair or regulation of 
G1 arrest are potential substrates  for apopain, including the 
apurinic-apyrimidinic endonuclease Ref-1  (28,  29),  uracil 
DNA  glycosylase, and  the  PI3-kinase  homologue  FRAP 
(see reference 4). 
ICE and its relatives are highly specific endoproteinases, 
and it should be noted that cleavage by such an enzyme need 
not destroy or inactivate a substrate molecule. It is known, 
for example, that ICE can activate apopain by proteolysis 
and apopain appears to be directly responsible for cleaving 
some or all of the downstream target molecules. Similarly, 
the cleaved substrates  of apopain may exhibit activities not 
found in the uncleaved molecules. In the case of  DNA-PKc~, 
cleavage by apopain  removes the  catalytic domain of the 
molecule from the region that interacts with Ku proteins. 
This catalytic domain retains basal catalytic activity (4) and 
because it is no longer locahzed to sites of DNA damage, it may have access to a different set ofsubstrates than does the 
DNA-PK holoenzyme. Similarly, PAR.P cleavage does not 
destroy the COOH-terminal  catalytic portion of the mole- 
cule  but  separates  it  from the  NH2-terminal  domain  that 
binds  DNA.  Surprisingly,  this  NHa-terminal  domain  may 
be biologically active independent  of the  catalytic  portion 
of the molecule and also independent  of its ability to bind 
DNA.  Schreiber et al.  (30)  found that,  compared with pa- 
rental  ceils,  cells  expressing  the  NH2-terminal  domain  of 
PARP  dramatically  increased  the  rate  of cell  doubling  in 
response  to  DNA  damage,  suggesting  that  the  transgene 
compromises  some  cell  cycle  checkpoint.  Cells  accumu- 
lated  at some point  after S phase  and  underwent  apoptosis 
and  DNA  recombination  at  an  elevated  rate.  These  same 
effects were observed with a mutant NH2-terminal domain 
lacking a zinc-finger required  for DNA  binding  (30).  Evi- 
dently,  this  portion  of the protein  can interact with  other 
molecules  in  addition  to  DNA,  with  profound  effects on 
cell cycle control.  A  crucial question  is whether the NH 2- 
terminal fragment released from PAP, P by apopain in vivo, 
which is smaller than the fragment engineered by Schreiber 
et al., exerts similar effects. 
Although the cleavage of ICE family targets during apop- 
tosis  facilitates  cell  death,  the  process  is  not  completely 
benign from the standpoint of the organism. A  subset of in- 
frequently  targeted  autoantigens  in  systemic  lupus  erythe- 
matosus are cryptic nuclear determinants  generated by the 
action ofapopain on such substrates as the U1-70 kD pro- 
tein and DNA-PKcs (10). How this subset ofepitopes is tar- 
geted for an autoimmune response is not known (31). How- 
ever, the observation of clustered autoantigens  suggests the 
active  participation  of cells  that  have  activated  apopain- 
dependent proteolysis but have not  (or not yet) undergone 
apoptosis. 
One unresolved issue is at what point apoptosis becomes 
irreversible  after the  activation  of the  ICE family protein- 
ases.  Clearly,  the  induction  of ICE  and  apopain  do  not 
necessarily  trigger  cell  death.  These  proteinases  have  nor- 
mal physiological  roles  in the  activation  of interleukin  113 
and of the sterol regulatory  element binding protein  tran- 
scription  factors  (32,  33).  It is  not  known  whether  other 
targets  of these proteinases  are cleaved under  these  condi- 
tions, but there is reason to suspect that even low levels of 
proteolysis  could  have  dramatic  effects  on  p53  function. 
Cells from A-T heterozygotes  have markedly reduced  in- 
duction of p53 compared to normal cells, and these patients 
are at increased risk of breast and ovarian cancer (34). These 
findings  suggest  that  p53  is  exquisitely  sensitive  to  ATM 
expression levels. If the induction of ICE family proteinases 
under physiological  conditions  can  compromise  DNA  re- 
pair  responses  or  generate  autoantigens  without  inducing 
apoptosis, the results could be of far greater consequence  to 
the organism than the death of the affected cell. 
Toward a Biochemistry of Life and Death 
The  twin  fields  of apoptosis  and  cell  cycle  research  are 
only  now  beginning  to  yield  detailed  biochemical  data. 
With the identification  of the ICE family proteinases,  their 
cleavage specificities and  some of their substrates,  one  can 
now formulate  testable predictions  about the physiological 
role of proteolysis in apoptosis.  For example,  if the  Casci- 
ola-lkosen  model  (4)  is  correct,  namely,  that  cleavage  of 
DNA  repair molecules  allows cells to apoptose efficiently, 
it  would  be  expected  that  cleavage-resistant  repair  mole- 
cules  would  extend  the  time  needed  for  apoptosis  to  be 
completed.  Fortunately,  animals  lacking  the  various  sub- 
strate  proteins  now  exist,  either  as  spontaneous  mutants 
(the SCID mouse, lacking DNA-PKcs) or by gene targeting 
(the PAP, P-deficient  mouse).  Mutant  versions  of the  pro- 
teins  that  lack  the  apopain  cleavage  site  can  now  be  de- 
signed and can be expressed in cultured cells or whole ani- 
mals,  alone or in  combination,  in the  presence  or absence 
of the wild-type protein.  Such experiments should provide 
a far more satisfying mechanistic  understanding  of the way 
that life-or-death decisions are made at the cellular level. 
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